The Road to Cures Series: Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma – Module 3 of 5

Program Overview

This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes.

This activity will cover the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.

Credit Expired

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the efficacy of targeted therapy in genetic subtypes of aggressive lymphoma


Activity Faculty


Louis M. Staudt, MD, PhD

Chief, Lymphoid Malignancies Branch
Director, Center for Cancer Genomics
National Cancer Institute
Bethesda, MD


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources